<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723629</url>
  </required_header>
  <id_info>
    <org_study_id>B2018-137R</org_study_id>
    <nct_id>NCT03723629</nct_id>
  </id_info>
  <brief_title>Progression of Untreated Pulmonary Ground Glass Opacity</brief_title>
  <official_title>Progression of Untreated Pulmonary Ground Glass Opacity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, about 2000 GGO patients will be included for a 5-year follow-up. The aim of
      this study is to elucidate the biological nature of pulmonary GGO lesion and provide evidence
      for GGO treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline GGO diameter</measure>
    <time_frame>6 months, 1year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Changes from baseline GGO diameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline GGO CT index.</measure>
    <time_frame>6 months, 1year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Changes from baseline GGO CT index.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>pulmonary GGO</arm_group_label>
    <description>Patients with pulmonary GGO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intercention</intervention_name>
    <description>No intercention</description>
    <arm_group_label>pulmonary GGO</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic out patients of thoracic surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35-80 years' old

          -  found pulmonary GGO with chest CT scan and CT follow-up after 3 months shows that the
             GGO remains

          -  Diameter of GGO &gt; 5mm and &lt; 3cm

          -  Solid component of GGO in pulmonary window &lt; 5mm

          -  signed informed consent form

        Exclusion Criteria:

          -  receiving immunosuppressor or steriods

          -  receiving chemo- or radio- therapy

          -  can not receive regular follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qun Wang</last_name>
    <phone>+86-64041990-2018</phone>
    <email>wang.qun@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Wang</last_name>
      <phone>+86-64041990-2018</phone>
      <email>wang.qun@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ground glass opacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

